Fernando Aguirre - 20 May 2026 Form 4 Insider Report for CVS HEALTH Corp (CVS)

Reporting relationship: Director
Issuer ticker: CVS
Reported as of: 20 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 May 2026, 17:39:40 UTC
Prior SEC filing: 19 May 2026
Next SEC filing: 02 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Fernando Aguirre

Filing notes and source

Key filing fact

Fernando Aguirre filed Form 4 for CVS HEALTH Corp (CVS) on 22 May 2026.

Key facts

This page summarizes Fernando Aguirre's Form 4 filing for CVS HEALTH Corp (CVS).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 22 May 2026, 17:39.

Change

Previous filing in this sequence was filed on 19 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001224983 Primary reporting owner

AGUIRRE FERNANDO

Relationship: Director
Address: ONE CVS DRIVE, WOONSOCKET
Signature: /s/ Fernando Aguirre
Signature date: 22 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CVS transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -30,437
Change %: -72%
Price: $93.78^*
Shares after: 12,076
Date: 20 May 2026
Ownership: Direct
Footnotes: F1

CVS transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -1,563
Change %: -13%
Price: $93.50^*
Shares after: 10,513
Date: 21 May 2026
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents weighted average purchase price for this group of purchases, which occurred on the same day. Multiple purchases were conducted, with prices ranging between $93.50 and $94.01 per share.

Footnote F2

Represents weighted average purchase price of 93.775 per share.